ATE205493T1 - N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden - Google Patents
N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische ligandenInfo
- Publication number
- ATE205493T1 ATE205493T1 AT97908719T AT97908719T ATE205493T1 AT E205493 T1 ATE205493 T1 AT E205493T1 AT 97908719 T AT97908719 T AT 97908719T AT 97908719 T AT97908719 T AT 97908719T AT E205493 T1 ATE205493 T1 AT E205493T1
- Authority
- AT
- Austria
- Prior art keywords
- alkyl
- disorders
- compounds
- hydrogen
- aminoalkyldibenzofuran
- Prior art date
Links
- 102000015554 Dopamine receptor Human genes 0.000 title 1
- 108050004812 Dopamine receptor Proteins 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000014094 Dystonic disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 208000010118 dystonia Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 239000003176 neuroleptic agent Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/608,259 US5710274A (en) | 1996-02-28 | 1996-02-28 | N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands |
| PCT/US1997/002895 WO1997031916A1 (en) | 1996-02-28 | 1997-02-26 | N-aminoalkyldibenzofurancarboxamides as dopamine receptor subtype specific ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE205493T1 true ATE205493T1 (de) | 2001-09-15 |
Family
ID=24435715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97908719T ATE205493T1 (de) | 1996-02-28 | 1997-02-26 | N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5710274A (de) |
| EP (1) | EP0891354B1 (de) |
| JP (1) | JP3176935B2 (de) |
| AT (1) | ATE205493T1 (de) |
| AU (1) | AU726310B2 (de) |
| CA (1) | CA2248269A1 (de) |
| DE (1) | DE69706660T2 (de) |
| ES (1) | ES2162257T3 (de) |
| WO (1) | WO1997031916A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| SK4782001A3 (en) | 1998-10-08 | 2001-11-06 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| US6506712B2 (en) | 2001-05-21 | 2003-01-14 | React, Llc | Method of manufacturing a multifunctional additive and using the same |
| TWI417095B (zh) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| CN1948298B (zh) * | 2006-11-09 | 2010-09-01 | 东南大学 | 一种多巴胺d3受体部分激动剂及其应用 |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| WO2008153573A1 (en) * | 2007-06-15 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use |
| KR20100080597A (ko) * | 2007-09-14 | 2010-07-09 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된-４-페닐-1ｈ-피리딘-2-온 |
| KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온 |
| CA2696948C (en) * | 2007-09-14 | 2013-04-30 | Jose Maria Cid-Nunez | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| EP2220083B1 (de) * | 2007-11-14 | 2017-07-19 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]-pyridin-derivate und ihre verwendung als positive allosterische modulatoren von mglur2-rezeptoren |
| CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| BRPI0921333A2 (pt) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos |
| EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2643320B1 (de) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridinderivate und ihre verwendung als positiv allosterische modulatoren des mglur2 receptors |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| KR102414246B1 (ko) | 2014-01-21 | 2022-06-27 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| US11299476B2 (en) | 2016-03-14 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof |
| EP3848351B1 (de) | 2016-03-14 | 2025-01-15 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Dopamin-d3-rezeptorselektive antagonisten/partielle agonisten, verfahren zur herstellung und verwendung davon |
| EP3849963A1 (de) | 2018-09-11 | 2021-07-21 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Dopamin-d3 -rezeptorselektive antagonisten/partielle agonisten und verwendungen davon |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3903116A (en) * | 1969-06-16 | 1975-09-02 | Richardson Merrell Inc | Bis-basic amides of dibenzofuran |
| US3867409A (en) * | 1969-06-16 | 1975-02-18 | Richardson Merrell Inc | Bis-basic esters of dibenzofuran |
| US3751390A (en) * | 1971-05-19 | 1973-08-07 | Aldrich Chem Co Inc | Substituted dibenzofuran |
| US4863921A (en) * | 1988-04-27 | 1989-09-05 | Rorer Pharmaceutical Corporation | Dibenzofurancarboxamides and their pharmaceutical compositions and methods |
| EP0494140A4 (en) * | 1989-09-27 | 1992-09-02 | Rorer International (Holdings), Inc. | Dibenzofurancarboxamides |
| MX9306311A (es) * | 1992-10-13 | 1994-04-29 | Smithkline Beecham Plc | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen |
| US5395835A (en) * | 1994-03-24 | 1995-03-07 | Warner-Lambert Company | Naphthalamides as central nervous system agents |
-
1996
- 1996-02-28 US US08/608,259 patent/US5710274A/en not_active Expired - Fee Related
-
1997
- 1997-02-26 WO PCT/US1997/002895 patent/WO1997031916A1/en not_active Ceased
- 1997-02-26 CA CA002248269A patent/CA2248269A1/en not_active Abandoned
- 1997-02-26 DE DE69706660T patent/DE69706660T2/de not_active Expired - Fee Related
- 1997-02-26 EP EP97908719A patent/EP0891354B1/de not_active Expired - Lifetime
- 1997-02-26 AT AT97908719T patent/ATE205493T1/de active
- 1997-02-26 JP JP53106297A patent/JP3176935B2/ja not_active Expired - Fee Related
- 1997-02-26 ES ES97908719T patent/ES2162257T3/es not_active Expired - Lifetime
- 1997-02-26 AU AU20557/97A patent/AU726310B2/en not_active Ceased
-
1998
- 1998-01-09 US US09/005,285 patent/US5977367A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69706660D1 (de) | 2001-10-18 |
| US5710274A (en) | 1998-01-20 |
| AU2055797A (en) | 1997-09-16 |
| WO1997031916A1 (en) | 1997-09-04 |
| JP3176935B2 (ja) | 2001-06-18 |
| DE69706660T2 (de) | 2002-04-18 |
| CA2248269A1 (en) | 1997-09-04 |
| JPH11504947A (ja) | 1999-05-11 |
| US5977367A (en) | 1999-11-02 |
| ES2162257T3 (es) | 2001-12-16 |
| AU726310B2 (en) | 2000-11-02 |
| EP0891354B1 (de) | 2001-09-12 |
| EP0891354A1 (de) | 1999-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69706660D1 (de) | N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden | |
| ATE201676T1 (de) | N-azacycloalkylalkyldibenzothiophencarboxamide: spezifische liganden für dopaminrezeptorsubtypen | |
| ATE219068T1 (de) | Naphtylamides als zentralnervensystemmittel | |
| GEP20022676B (en) | 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors | |
| ATE282410T1 (de) | Thyromimetika als mittel gegen fettleibigkeit | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| BR0007424A (pt) | Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto | |
| ATE447970T1 (de) | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors | |
| GB0225474D0 (en) | Therapeutic agents | |
| ATE168007T1 (de) | Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole | |
| DE69505542D1 (de) | 3-benzoylbenzofuran-derivate als thyroidhormonantagonisten | |
| DE60206198D1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
| SG151260A1 (en) | 5-substituted-2-phenylamino-benzamides as mek inhibitors | |
| ATE455773T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| DE60234919D1 (de) | 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| BR0315837A (pt) | Derivados de amida de ácido heteroaril-hexanóico como agentes imunomoduladores | |
| DK0432648T3 (da) | Isatinderivater, deres fremstilling og anvendelse | |
| EA200000242A1 (ru) | Применение фанхинона для лечения болезни альцгеймера | |
| BR9906719A (pt) | "n-óxidos de compostos heterocìclicos com atividade inibidora de tnf e de pde-iv" | |
| AU2459897A (en) | Novel n-aminoalkyl-1-biphenylenyl-2-carboxamides; new dopamine receptor subtype specific ligands | |
| DE69822937D1 (de) | Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen | |
| BR9911280A (pt) | Aril piperazinas, piperidinas e tetraidro piridinas substituìdas com ciclo alquila como agentes serotonérgicos | |
| DE69911373D1 (de) | Azetidincarboxamidderivate zur behandlung von zns-erkrankungen | |
| ATE283269T1 (de) | 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems |